Health knowledge made personal
Join this community!
› Share page:
Search posts:

Use of Razoxane for the Treatment of Alzheimer's Disease

Posted Aug 31 2008 5:00pm

Description of Invention:
Abnormalities in the metabolism of the transition metals, iron and copper, have been demonstrated to play a crucial role in the pathogenesis of various neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD). Excessive iron accumulation in the brain occurs in both AD and PD. High levels of reactive iron can increase oxidative stress-induced neuronal vulnerability, increase the toxicity of environmental or endogenous toxins, and accelerate hallmark pathologies of these diseases.

As an example among many, the expression level of amyloid-beta precursor protein (APP) that generates the AD neurotoxic peptide, amyloid-beta (A-beta), is regulated in large part by iron levels. APP mRNA has an iron response element (IRE) in its 5'-untranslated region, and cleavage of APP to release different amyloidogenic and non-amyloidogenic peptide forms involves metalloproteases.

Elevated A-beta levels as well as plaques formed by aggregation of A-beta involve iron, and play a significant role in degeneration of the brain seen in AD. Chelators can reduce both the generation and aggregation of A-beta. Razoxane, a bisdioxopiperazine, is an orally active metal chelator approved for the treatment of cancer, where it and dexrazoxane have been effectively used for decades. In neuronal cell culture models, razoxane induced dose-dependent reductions in APP and A-beta levels without toxicity. In animal experiments (transgenic mice expressing human A-beta), razoxane substantially reduced A-beta 1-40 and 1-42 in brain by up to 46% without toxicity following once daily, 21 day administration.

The claimed invention is the novel use of razoxane and other bisdioxopiperazines to reduce amyloid-beta peptide levels, reduce aggregation of alpha-synuclein and tau protein, and reduce abnormal protein folding or aggregation for the treatment of AD and related diseases with protein aggregation pathology. Since razoxane has been approved for humans use, it could be more quickly developed as a treatment for AD, PD and other diseases.

Development Status:
Clinical safety data and pre-clinical efficacy data for treatment of Alzheimer's disease.

Nigel H Greig (NIA)

Patent Status:
HHS, Reference No. E-216-2007/0
US, Application No. 12/308,027 filed 08 Jun 2007

Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Institute on Aging, Laboratory of Neurosciences, Section on Drug Design & Development, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize razoxane and analogues for the treatment of neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases. Please contact Nigel H. Greig ( ) for more information.

Central Nervous System
Central Nervous System - Therapeutics

For Additional Information Please Contact:
Norbert Pontzer Ph.D., J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 23,
Rockville, MD 20852
United States
Phone: 301-435-5502
Fax: 301-402-0220

Ref No: 1816

Updated: 09/2008

Post a comment
Write a comment:

Related Searches